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See Article, pages 1017–1024Increased portal pressure is the major factor driving the clinical
course of cirrhosis [1]. This concept seems obvious as most
(severe) clinical consequences of chronic liver disease are related
to portal hypertension – including varices, bleeding from varices
or from portal hypertensive gastropathy/colopathy, ascites, spon-
taneous bacterial peritonitis, hepatorenal syndrome, hepatic
encephalopathy, hepatopulmonary syndrome, and porto-pul-
monary hypertension [2]. However, it has not been until very
recently demonstrated by longitudinal studies assessing the nat-
ural history of portal hypertension in patients with cirrhosis and
more important [3,4], its reversion by effective portal pressure
reduction by medical treatment [5,6]. The best predictor of devel-
opment of these complications (or clinical ‘‘decompensation’’) so
far detected is an increase of the hepatic venous pressure gradi-
ent (HVPG) of at least 10 mmHg, which represents the threshold
value for the complications of portal hypertension to occur
[1,3,4].
In this issue of the Journal of Hepatology, Rotic and his co-
workers from Toulouse [7] go a step further by showing that
one can detect these patients with poor prognosis – who there-
fore are candidates to portal hypotensive therapy – just by look-
ing at something so simple and ‘‘clean’’ as transient elastography
(TE), that had the same predictive value as HVPG, which is a
much more invasive, sophisticated, and expensive measurement.
Bravo!
Certainly the study has limitations. These include: (a) a small
number of patients (100, and only 65 of them had cirrhosis,
which is the relevant population as only three non-cirrhotic
had any event during follow-up), (b) it is likely to have some
selection bias, as suggested by the high percentage of patients
who already had varices (72% of the compensated cirrhotics)
and their unusually high risk of decompensation (55% at 2 year;
as compared with the 40% prevalence of varices and 29% inci-
dence of decompensation in a larger study in totally compensated
cirrhotics with an 8-year follow-up [3,4]), (c) the potential impact
of treatments for portal hypertension offered to these patients on
the incidence of events, (d) the lack of explanation on the method
of imputation of TE values in the patients where this measure-
ment was not possible, and (e) the role of different etiologies rais-Journal of Hepatology 20
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Open access under CC BY-NC-ND license.ing the cut off value of TE to detect a HVPGP10 mmHg. Indeed, a
key issue is that the 21.1 kPa cut off value to detect patients with
clinically signiﬁcant portal hypertension (deﬁned by an
HVPGP10 mmHg) has not been conﬁrmed by other investiga-
tors using the same equipment. Thus, Vizzutti et al. [8] showed
this cut off to be much lower (13.6 kPa) in a study done in
patients with chronic liver disease due to hepatitis C, and we
do have very similar data at our institution (Berzigotti et al.,
unpublished data). Also, Kazemi et al. showed that French
patients with hepatitis C related cirrhosis could have oesophageal
varices (and therefore very signiﬁcant portal hypertension) with
TE values well below 21.1 kPa, [9] something that was also found
by Vizzutti et al. [8]. Therefore, if we were to use the results of
this study as a guide, we would classify as low risk some of the
high risk patients with cirrhosis due to hepatitis C infection,
which would diminish the predictive value of the test (and its
clinical applicability).
In summary, the results of the study that apparently are so
clear-cut and robust – which in practice would overcome all its
limitations – are not so rock hard as the livers from which the
information was drawn [10].
This does not mean that the study is not useful. On the con-
trary, I think this study makes a lot of sense; actually I would
be very surprised if such study would have yielded opposite
results. This is because many studies have shown that TE corre-
lates well with HVPG, especially when HVPG is <10–12 mm Hg
[8,11,12]. Given this correlation, it is logical that TE can predict
patients with HVPG above threshold, as already demonstrated
by the same group back in 2008 [12]. The only point in discussion
is which the optimal cut off value is and to what extent it is dis-
ease speciﬁc or may be inﬂuenced by other factors. What is unde-
niable is the prognostic value of TE in cirrhosis. It is now clear
that the harder your liver is, the harder your life will be. . . and
the harder will be the task for the attending physician that shall
face the problem of ameliorating this poor prognosis.
On the other hand, the ﬁnding that TE predicts the occurrence
of events during the follow up may appear obvious if TE can pre-
dict a marked HVPG elevation. It can further be argued that if
something is obvious, then there is no need of demonstrating
it. However, medicine is not (totally) an exact science and taking
the pain of demonstrating what at ﬁrst glance may seem obvious
is wise and reassuring. The study under consideration has the
merit of showing the right path for what would be a big step for-
ward. Actually, two independent studies suggest that increased11 vol. 55 j 955–956
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TE values (again with different cut off values) predict an
increased risk of hepatocellular carcinoma during the follow-up
of patients with chronic liver disease due to hepatitis C [13]
and hepatitis B [14], which is also correlated with the degree of
HVPG elevation [15].
It is debatable whether measurement of TE by Fibroscan will
be the right technique to use. Fibroscan has been widely used
in Europe, but there is large room for technological advances that
can make elastography measurements more applicable and reli-
able. Actually, it has been shown that magnetic resonance elas-
tography [16] is more accurate and applicable than transient
elastography by Fibroscan (but much more costly), and more
recently, virtual touch elastography using acoustic radiation force
impulse imaging (ARFI) is emerging as a reliable technique with-
out the practical limitations inherent to MR elastography [17,18].
Finally, whether measuring TE can substitute measurements
of HVPG in other situations, for example in assessing the feasibil-
ity of liver resection surgery in patients with cirrhosis [19], or in
assessing the response to the medical treatment of portal hyper-
tension [20] would have to be speciﬁcally investigated, as essen-
tially there is no solid data on these points. The same hold true
for the question on whether new serum ﬁbrosis markers may also
be used to non-invasively detect when a patient with chronic
liver disease is at risk of clinical complications aggravating his
prognosis.Conﬂict of interest
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